JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
145.43
-0.48 (-0.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close145.91
Open145.49
Bid0.00 x 900
Ask0.00 x 800
Day's Range144.12 - 147.34
52 Week Range118.62 - 148.99
Volume9,444,459
Avg. Volume7,169,367
Market Cap390.04B
Beta (3Y Monthly)0.32
PE Ratio (TTM)255.59
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.48%)
Ex-Dividend Date2018-11-26
1y Target Est148.11
Trade prices are not sourced from all markets
  • Is Johnson & Johnson (JNJ) A Good Stock According To Hedge Funds?
    Insider Monkey2 hours ago

    Is Johnson & Johnson (JNJ) A Good Stock According To Hedge Funds?

    “Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Here's Why BeiGene Stock Rose 21.7% in November
    Motley Fool7 hours ago

    Here's Why BeiGene Stock Rose 21.7% in November

    A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.

  • 19 Best Stocks to Buy for 2019
    Kiplinger3 days ago

    19 Best Stocks to Buy for 2019

    Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock picks. Investors looking for the best stocks to buy for 2019 should start with these 19 companies. These firms, ranging from a money-center bank to a bargain-basement retailer, have solid prospects in 2019. We've also listed five stocks you should consider parting ways with. Check them out. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • Reuters3 days ago

    PRESS DIGEST-New York Times business news - Dec 7

    The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - The ride-hailing company Lyft said on Thursday it ...

  • Johnson & Johnson (JNJ) Stock Moves -0.08%: What You Should Know
    Zacks3 days ago

    Johnson & Johnson (JNJ) Stock Moves -0.08%: What You Should Know

    Johnson & Johnson (JNJ) closed at $145.91 in the latest trading session, marking a -0.08% move from the prior day.

  • Can You Hide in Johnson and Johnson Stock Amid the Turmoil?
    InvestorPlace3 days ago

    Can You Hide in Johnson and Johnson Stock Amid the Turmoil?

    Markets gave investors quite a pump fake earlier this week. After the strong rally on Monday, investors believed that stocks would have a relief rally heading into 2019. While the action caused investors’ sentiment to drop sharply, not all stocks had a horrible day.

  • Reuters3 days ago

    J&J unit to pay $360 million to U.S. to resolve charity kickback probe

    A Johnson & Johnson (JNJ.N) unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday. The settlement with Actelion Pharmaceuticals US Inc, which became a subsidiary of J&J following a 2017 acquisition, was the largest so far to result from an industry-wide probe into drugmakers' support of patient assistance charities. The government said Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co-pay obligations of thousands of Medicare patients using its pulmonary artery hypertension treatments Tracleer, Ventavis, Veletri and Opsumit.

  • J&J unit to pay $360 million to U.S. to resolve charity kickback probe
    Reuters3 days ago

    J&J unit to pay $360 million to U.S. to resolve charity kickback probe

    A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday. The settlement with Actelion Pharmaceuticals US Inc, which became a subsidiary of J&J following a 2017 acquisition, was the largest so far to result from an industry-wide probe into drugmakers' support of patient assistance charities. The government said Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co-pay obligations of thousands of Medicare patients using its pulmonary artery hypertension treatments Tracleer, Ventavis, Veletri and Opsumit.

  • Peninsula drug maker to pay $360M to settle Justice Department claims
    American City Business Journals3 days ago

    Peninsula drug maker to pay $360M to settle Justice Department claims

    The company gave a nonprofit foundation money to cover Medicare copays for its pulmonary arterial hypertension drugs as it hiked the prices of those drugs and steered Medicare patients away from the company's own free drug program to the foundation.

  • Houston cancer pharma co. begins Phase I trials after $6M Series B
    American City Business Journals3 days ago

    Houston cancer pharma co. begins Phase I trials after $6M Series B

    Iterion Therapeutics rebranded itself from Beta Cat Pharmaceuticals in the last week or two, according to president and CEO Rahul Aras.

  • Associated Press3 days ago

    Drug company Actelion to pay $360M in kickback probe

    BOSTON (AP) — A pharmaceutical company has agreed to pay $360 million to resolve allegations that it used a charitable foundation to pay kickbacks to Medicare patients.

  • Where Does Apple Rank in the Wearables Market?
    Market Realist3 days ago

    Where Does Apple Rank in the Wearables Market?

    Apple (AAPL) ventured into selling wearable devices such as smartwatches to diversify its hardware business beyond the mature markets for smartphones and personal computers. Xiaomi shipped 6.9 million wearables, representing a 21.5% share of the global market. Some 32 million wearable devices were shipped globally in the third quarter, showing that the wearables market had expanded 21.7% YoY in the period.

  • AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
    Zacks4 days ago

    AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

    IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

  • Financial Times4 days ago

    [$$] Actelion Pharmaceuticals agrees to pay $360m in DoJ settlement

    has agreed to pay $360m to settle civil claims it used a charity to pay illegal kickbacks to patients in the US, the Department of Justice announced on Thursday. last year, was accused of using a charitable foundation to help Medicare patients make payments for its prescription drugs that treat high blood pressure. The settlement on Thursday is the largest agreed so far in the US government’s investigation of the use of charitable foundations in the pharmaceutical industry.

  • GuruFocus.com4 days ago

    Johnson & Johnson: An Excellent Business Selling at a Rational Price

    Warning! GuruFocus has detected 2 Warning Sign with HA. When you read something like that, a company like Johnson & Johnson (JNJ) comes to mind. Johnson & Johnson has grown earnings per share by a compound annual rate of 10.5% per year over the last two decades, by 6% per annum in the last decade and 8.2% annualized over the last five years.

  • J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
    Zacks5 days ago

    J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

    J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.

  • Mylan Expands Recall of Valsartan to All Unexpired Lots
    Zacks5 days ago

    Mylan Expands Recall of Valsartan to All Unexpired Lots

    Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

  • Can Celgene and bluebird bio Survive a Two-Pronged Attack?
    Motley Fool5 days ago

    Can Celgene and bluebird bio Survive a Two-Pronged Attack?

    A promising program these partners are working on is under assault from two different directions.

  • 10 Defensive Stocks to Protect Your Portfolio in 2019
    InvestorPlace5 days ago

    10 Defensive Stocks to Protect Your Portfolio in 2019

    Following the highly anticipated sit-down between President Donald Trump and Chinese President Xi Jinping at the G-20 summit, investors received a respite: the White House says both leaders agreed to temporarily halt escalating sanctions. Trump has never enjoyed a reputation as a steady, calm hand in the face of stress or provocation. While the agreement facilitates a 90-day ceasefire regarding the ongoing trade war, investors should adopt a measured approach.

  • J&J Strikes Deal with argenx to Co-Develop Cancer Antibody
    Zacks5 days ago

    J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

    Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.

  • TheStreet.com5 days ago

    P&G, Johnson & Johnson, Verizon Hold Strongest on Ugly Day for Dow Jones

    The U.S. stock market was getting rocked Tuesday, as investors grew wary of the promising trade talks that came out of the G-20 meeting and the inverted 3-year and 5-year treasury yields. But there's a clear sign of where investors' appetite could soon be headed atop the leader board.

  • Better Buy: Intuitive Surgical vs. Johnson & Johnson
    Motley Fool5 days ago

    Better Buy: Intuitive Surgical vs. Johnson & Johnson

    Are aging boomers a bigger boon to a robotic surgery leader or a century-old healthcare conglomerate?